Home
About us
News
Products
Innovation
CMO/CDMO Services
Contact
中文
undefined
Jiudian Hongyang Pharmaceutical have Market Authorization of Ketoprofen API from NMPA
On 5th Dec, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of Ketoprofen (Y20220000371) API from NMPA.
06
2023
/
12
Jiudian Hongyang Pharmaceutical obtained registration No. of Avobenzone and Sucralose from NMPA
Jiudian Hongyang, which is wholly-owned subsidiary of Jiudian Pharmaceutical, obtained registration No. of Avobenzone (F20230000420) and Sucralose (F20230000345) from NMPA in Oct, 2023.
25
10
Hunan Jiudian Pharmaceutical have Market Authorization of Loxoprofen Sodium Oral Solution from NMPA
Oct 24, 2023, Jiudian Pharmaceutical have drug license of Loxoprofen Sodium Oral Solution from NMPA. We are the first company which obtain it.
Jiudian Hongyang Pharmaceutical had Market Authorization of Flurbiprofen from NMPA
On 29th Aug, 2023, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had market authorization of Flurbiprofen (Y20200001121) from NMPA.
31
08
Jiudian Hongyang Pharmaceutical obtained registration No. of Polaprezinc from NMPA
Jiudian Hongyang, which is wholly-owned subsidiary of Jiudian Pharmaceutical, had registration no. of Polaprezinc (Y20230000678) from NMPA recently.
Jiudian Pharmaceutical Semi-annual Report
On August 16, Jiudian Pharmaceutical released its 2023 half-year performance report. In the first half of the year, the company realized operating income of 1.218 billion RMB, an increase of 18.11% year-on-year; attributable net profit of 198 million RMB, an increase of 52.29% year-on-year, of which non-deductible attributable net profit of 178 million RMB, an increase of 43.35% year-on-year. The performance report shows that the company's various operating indicators are performing well, and continue to maintain a steady growth trend.
16
Jiudian Pharmaceutical on the list of Forbes Asia Best Under A Billion 2023
Recently, Forbes released the 2023 Asia's Top 200 Small and Medium-sized Listed Companies list, 59 Chinese companies including 30 mainland companies were on the list, and Jiudian Pharmaceuticals and Yanjin Puzi became the representatives of Hunan enterprises among them.
11
